Looking to create and expand a medical advisory board to assist in reaching new patients and clinics, Acreage Holdings (CSE: ACRG.U; OTCQX: ACRGF) just created the role of Chief Medical Officer.
Today the company announced that the new position in senior management will be filled by Dr. Corey Burchman, who moves into the job after working as Assistant Professor of Anesthesiology and Pain Medicine at Dartmouth’s Geisel School of Medicine.
A Navy veteran, Dr. Burchman has 33 years of experience in the medical field, completing his residency and fellowship at Harvard Medical School. He will report directly to Acreage’s COO while working to reduce risks and increase options for medical patients with new product rollouts.
Discussing what he offers the Acreage management team, Dr. Burchman issued this statement:
Prior to joining the Acreage team, Dr. Burchman authored a 2017 study that has become part of a growing body of evidence showing cannabis potentially has a major role to play in fighting the opioid crisis.
Released in the Journal of Psychopharmacology, the study found that medical cannabis patients in New England saw reductions in usage of opioids, antidepressants, alcohol, and anxiety medication.
Other cannabis companies across the industry in both the U.S. and Canada have been involved in funding similar research.
Back in January, Aleafia Health Inc. (TSXV: ALEF, OTC: ALEAF) released a peer-reviewed study in the journal Cannabis and Cannabinoid Research that showed cannabis usage in patients led to decreased usage and dependence on benzodiazepines.
Acreage has experienced several bumps in the road while trying to further their medical patient outreach lately.
Earlier this year, a 30-second Acreage commercial touting the benefits of cannabis for seizure patients and those with chronic pain issues was rejected by CBS for the 2019 Super Bowl ad line-up. The company later released a longer 60-second version of the ad online via YouTube.
The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Grizzle hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.